Back to top
more

AnaptysBio (ANAB)

(Real Time Quote from BATS)

$19.88 USD

19.88
471,452

-1.80 (-8.30%)

Updated Nov 4, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug

by Zacks Equity Research

Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

by Zacks Equity Research

Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

by Zacks Equity Research

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment

by Zacks Equity Research

Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.

Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug

by Zacks Equity Research

Data from an early-stage study shows that treatment with Karuna's (KRTX) KarXT was not associated with clinically meaningful increases in blood pressure in schizophrenia patients.

Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer

by Zacks Equity Research

Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.

Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of -15.91% and 6.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -13.58% and 24.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -51.92% and 65.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 0% and 19.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 45.1% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

GSK's Jemperli Effective Against First-Line Endometrial Cancer

by Zacks Equity Research

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q4 Earnings Top Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 17.24% and 0.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal

by Zacks Equity Research

GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?